Top Page
Esperion
(NASDAQ:ESPR)
Esperion (ESPR) vs. SPDR S&P 500 ETF (SPY)
Esperion Business Overview & Revenue Model
Esperion Earnings Call Summary
Esperion Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 268.13M | 332.31M | 116.33M | 75.47M | 78.45M | 227.55M |
| Gross Profit | 173.06M | 263.71M | 73.07M | 48.51M | 64.23M | 225.16M |
| EBITDA | -24.59M | 7.57M | -150.11M | -176.35M | -222.14M | -120.33M |
| Net Income | -96.09M | -51.74M | -209.25M | -287.82M | -318.82M | -166.19M |
Balance Sheet | ||||||
| Total Assets | 347.08M | 343.82M | 205.80M | 247.94M | 381.59M | 353.26M |
| Cash, Cash Equivalents and Short-Term Investments | 86.06M | 144.76M | 82.25M | 124.78M | 208.89M | 304.96M |
| Total Debt | 146.45M | 591.21M | 540.95M | 260.95M | 260.20M | 185.41M |
| Total Liabilities | 780.59M | 732.54M | 660.79M | 571.72M | 578.53M | 449.39M |
| Stockholders Equity | -433.51M | -388.72M | -454.99M | -1.34B | -1.11B | -838.82M |
Cash Flow | ||||||
| Free Cash Flow | -124.49M | -23.97M | -135.49M | -174.83M | -263.81M | -98.55M |
| Operating Cash Flow | -124.33M | -23.65M | -135.49M | -174.83M | -263.81M | -85.18M |
| Investing Cash Flow | -167.00K | -317.00K | 42.50M | 8.10M | -50.48M | 21.36M |
| Financing Cash Flow | 21.25M | 86.48M | 50.46M | 32.61M | 268.22M | 201.72M |
Esperion Technical Analysis
Esperion Risk Analysis
Esperion Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $604.35M | 7.34 | 43.61% | ― | 3.86% | -2.60% | |
| ― | $519.64M | 3.95 | 30.24% | ― | -22.74% | ― | |
| ― | $627.70M | ― | ― | ― | -3.48% | 36.57% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $576.58M | ― | -8.30% | ― | 0.70% | 15.62% | |
| ― | $540.41M | ― | -2.64% | ― | -4.21% | 7.78% | |
| ― | $439.21M | ― | -9999.00% | ― | 17.15% | -7.23% |
Esperion Corporate Events
On October 7, 2025, Esperion Therapeutics announced an underwritten public offering of 30,000,000 shares of its common stock at $2.50 per share, with an option for underwriters to purchase an additional 4,500,000 shares. The offering is expected to close around October 9, 2025, and aims to raise approximately $70.2 million, or $80.7 million if the option is fully exercised. The proceeds will primarily fund the commercialization of NEXLETOL and NEXLIZET, research and development, and general corporate purposes. This move is part of Esperion’s strategy to strengthen its financial position and support its ongoing operations and growth initiatives.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
On October 7, 2025, Esperion Therapeutics announced an updated corporate presentation outlining their strategic plans to expand the Bempedoic Acid franchise globally. The company has secured key ANDA settlements extending exclusivity until April 19, 2040, and is implementing a balanced engagement strategy to boost physician adoption. Esperion aims to transition into a cash-generating pharmaceutical company by advancing its development pipeline and exploring potential acquisitions. The company reported its first quarter of operating income from ongoing business in Q2 2025, driven by increased product adoption and geographic expansion, supporting its profitability objectives.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Esperion Therapeutics, Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for the delay is the company’s need for additional time to complete its financial closing procedures, following the identification and correction of errors in its earnings release. Esperion expects to file the report no later than five calendar days after the prescribed due date. The company has not indicated any significant changes in financial results from the previous year. Ongoing compliance efforts are being managed by CEO Sheldon L. Koenig, who has signed the notification.
The most recent analyst rating on (ESPR) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Esperion stock, see the ESPR Stock Forecast page.
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing oral, non-statin medications for cardiovascular disease prevention, particularly for patients with elevated LDL cholesterol levels. In its second quarter of 2025, Esperion reported a 12% year-over-year increase in total revenue, reaching $82.4 million, with U.S. net product revenue growing by 42% to $40.3 million. The company also achieved its first quarter of operating income from ongoing operations, marking a significant milestone in its financial performance. Key highlights include settlement agreements preventing generic versions of its drug NEXLETOL from entering the market before 2040 and strategic expansions in international markets, including Japan and Europe. Esperion’s research and development expenses decreased by 37% compared to the previous year, and the company reduced its net loss significantly from $61.9 million in Q2 2024 to $4.8 million in Q2 2025. Looking ahead, Esperion anticipates achieving sustainable profitability by the first quarter of 2026, driven by continued revenue growth and strategic market expansions.
Esperion Therapeutics’ recent earnings call exuded a positive sentiment, underscored by robust growth in U.S. sales and successful marketing strategies. The company demonstrated significant progress in international markets, with strategic initiatives driving increased revenue and market penetration. Despite a slight dip in collaboration revenue, the overall positive developments and promising future prospects were the focal points of the discussion.